Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > FDA is short-sighted on compounding GLP-1s
Health and Wellness

FDA is short-sighted on compounding GLP-1s

Last updated: November 19, 2024 11:08 am
Share
FDA is short-sighted on compounding GLP-1s
SHARE

The controversy surrounding the drug Makena and the FDA’s response to it highlights the complex issues surrounding pharmacy compounding. While compounding plays a crucial role in tailoring medications to individual patients’ needs, it was never intended to provide price competition for branded drugs. The FDA’s decision to allow pharmacies to compound their own versions of Makena in response to public backlash over the drug’s high cost set a precedent that could undermine the agency’s broader public health obligations.

The recent debate over the compounding of GLP-1 drugs used for weight loss further underscores the challenges facing the FDA. Initially allowing pharmacies to compound these drugs due to shortages, the agency later cited the high cost of the branded drugs as a reason to continue compounding. This decision raises concerns about the FDA’s role in regulating compounded drugs and ensuring patient safety.

The Drug Quality and Security Act (DQSA), enacted in 2013, sought to address safety concerns related to pharmacy compounding in response to a meningitis outbreak caused by contaminated compounded drugs. The law established standards for compounding pharmacies to ensure the quality and sterility of compounded drugs. However, questions remain about the oversight of pharmacies compounding large volumes of drugs and shipping them across the country, especially when these pharmacies do not meet the FDA’s good manufacturing practices.

The FDA’s enforcement of the DQSA has been met with opposition from some members of Congress concerned about the economic impact on small pharmacies. While these pharmacies play a vital role in rural communities, ensuring the safety of compounded medicines remains a priority. The FDA must balance patient access to affordable medications with ensuring the quality and safety of compounded drugs.

See also  Western diet causes inflammation while traditional African foods protect, new study finds

Ultimately, the FDA’s regulatory decisions on pharmacy compounding should prioritize patient safety and quality standards over concerns about drug pricing. Allowing pharmacies to compound drugs based on cost considerations sets a dangerous precedent that could compromise patient care. As the FDA navigates the complex landscape of pharmacy compounding, it must uphold its commitment to protecting public health and ensuring the safety of compounded medications. The recent decision by the Food and Drug Administration (FDA) regarding the approval of Makena and potentially now tirzepatide has raised concerns about the agency’s ability to maintain control over critical policies in the future. The precedent set by these decisions could have far-reaching implications for the FDA and its regulatory authority.

Former FDA Commissioner Scott Gottlieb, who is now a senior fellow at the American Enterprise Institute, has expressed his concerns about the potential impact of these decisions. As a physician and former head of the FDA, Gottlieb understands the importance of maintaining strict regulatory standards to ensure the safety and efficacy of pharmaceutical products.

The approval of Makena, a drug used to reduce the risk of preterm birth in certain pregnant women, has sparked controversy due to questions about its effectiveness and safety. Despite concerns raised by some experts, the FDA decided to approve the drug, setting a precedent that could make it difficult for the agency to deny similar drugs in the future.

Now, with the potential approval of tirzepatide, a drug being developed for the treatment of type 2 diabetes, the FDA faces another critical decision. If tirzepatide is approved despite lingering safety concerns, it could further weaken the agency’s ability to maintain control over its regulatory policies.

See also  Common jobs held by immigrant women may put them at increased risk of breast cancer

The implications of these decisions go beyond the specific drugs in question. They raise broader questions about the FDA’s ability to uphold its mandate to protect public health and safety. If the agency continues to approve drugs with questionable efficacy or safety profiles, it could erode public trust in its regulatory processes.

Gottlieb’s expertise and experience give weight to his concerns about the precedent set by the FDA’s recent decisions. As a board member of Pfizer and a partner at New Enterprise Associates, he understands the complexities of the pharmaceutical industry and the challenges faced by regulatory agencies.

In conclusion, the FDA’s recent decisions regarding Makena and potentially tirzepatide have raised significant concerns about the agency’s ability to maintain control over critical policies in the future. The precedent set by these decisions could have far-reaching implications for the FDA and its regulatory authority, highlighting the importance of upholding strict standards to protect public health and safety.

TAGGED:compoundingFDAGLP1sshortsighted
Share This Article
Twitter Email Copy Link Print
Previous Article LeBron James fan and NBA analyst says 4x NBA champ is “big part” of Lakers’ problem amid horrid road stretch LeBron James fan and NBA analyst says 4x NBA champ is “big part” of Lakers’ problem amid horrid road stretch
Next Article Trump to Declare National Emergency, Use Military to Help at Border Trump to Declare National Emergency, Use Military to Help at Border
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Interview with Former AfD MP Dr. Heinrich Fiechtner: When Satire Becomes a Crime; Inside the Show Trials of Germany’s COVID Dissidents (Part I) | The Gateway Pundit | by Guest Contributor

This interview conducted by Alexander Junger was initially published by Eagle Eye Explore on September…

September 25, 2025

Engineer restores pay phones for free public use : NPR

Vermont Representative Philip Jay Hooper, who represents Orange County, makes a call using one of…

August 4, 2025

This Lego Brick Is About the Size of a Human White Blood Cell. It Just Became the World’s Smallest Sculpture

David A. Lindon, an English artist, has recently broken the world record for creating the…

March 24, 2025

Blue Origin says New Glenn on track to launch before end of 2024

Blue Origin Awaits Regulatory Approval for New Glenn Launch Blue Origin has announced that it…

December 9, 2024

‘The Hit List’ Hosts Rochelle and Marvin Humes Sign With WME for Representation (EXCLUSIVE)

WME The renowned British entertainment duo Rochelle and Marvin Humes are now under the representation…

October 8, 2025

You Might Also Like

IVF research, FDA vouchers, dementia: Morning Rounds
Health and Wellness

IVF research, FDA vouchers, dementia: Morning Rounds

October 31, 2025
Nearly 1 in 5 urinary tract infections linked to contaminated meat
Health and Wellness

Nearly 1 in 5 urinary tract infections linked to contaminated meat

October 31, 2025
Cigna Profits Hit Nearly  Billion Despite Rising Costs
Health and Wellness

Cigna Profits Hit Nearly $2 Billion Despite Rising Costs

October 30, 2025
For cardiac health, exercise benefits women more than men
Health and Wellness

For cardiac health, exercise benefits women more than men

October 30, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?